Search

Your search keyword '"Freeman, Gordon J."' showing total 1,869 results

Search Constraints

Start Over You searched for: Author "Freeman, Gordon J." Remove constraint Author: "Freeman, Gordon J."
1,869 results on '"Freeman, Gordon J."'

Search Results

51. Formate supplementation enhances anti-tumor CD8+ T cell fitness and efficacy of PD-1 blockade

52. The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy

56. Down-regulation of CTLA-4 by HIV-1 Nef protein.

64. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

65. Proceedings of the third international molecular pathological epidemiology (MPE) meeting

66. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

67. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

69. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.

71. Cyclin DCDK4 kinase destabilizes PD-L1 via cullin 3SPOP to control cancer immune surveillance

74. Supplementary Table from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

75. Data from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

76. Abstract 886: Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects

77. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

78. Supplementary Figure from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer

79. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

80. Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

81. Data from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer

82. Data from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

84. Supplementary Table S2 from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

85. Figure S2 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

86. Supplementary Table S2 from MicroRNA MIR21 and T Cells in Colorectal Cancer

87. Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

88. Data from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

89. Data from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

90. Data from MicroRNA MIR21 and T Cells in Colorectal Cancer

91. Data from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

92. Supplemental Tables 1 and 2 from Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes

93. Supplemental Figures 1-4 from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

94. Supplementary Figures 1 through 7, Supplementary Methods from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

95. Supplementary Tables from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

96. Supp. Movie 3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

97. Supplementary Table 5 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

98. Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

99. Table S1 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

100. Supplemental Figure and Table Legends from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Catalog

Books, media, physical & digital resources